Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Datopotamab Deruxtecan Dato-DXd combined with Rilvegostomig, or Rilvegostomig alone, compared with Pembrolizumab alone as first-line treatments for people with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC. Participants must have high PD-L1 expression tumor cells 50% and no actionable genomic mutations. This is a Phase III, randomized, open-label global study focusing on these treatments for this specific lung cancer type. Participants will be assigned to one of three groups one receiving Dato-DXd plus Rilvegostomig, another receiving Rilvegostomig alone, and a third receiving Pembrolizumab alone. All treatments are given by intravenous infusion every three weeks on Day 1 of each 21-day cycle. The study will monitor participants over several years to compare these therapies as first-line options. During the study, participants will undergo regular assessments including imaging and tumor sampling to measure progression-free survival and overall survival, focusing on those with TROP2 biomarker positivity. Other evaluations include response rates, duration of response, lung cancer symptoms, quality of life, physical functioning, pharmacokinetics, and immunogenicity over approximately 4 to 6 years. Safety monitoring and long-term follow-up are part of the participant involvement.
Actively Recruiting
Researchers are studying two experimental drugs, REGN7508 and REGN9933, in people with atrial fibrillation, a condition where the heart beats irregularly and too fast. The study aims to see how these drugs work to prevent blood clots compared to apixaban, a currently available medicine. The research also looks at potential side effects, how well the drugs reduce stroke risk, drug levels in the blood, and whether the body develops antibodies that might affect the drugs action or safety. Participants will be randomly assigned to receive either REGN7508, REGN9933, or apixaban. All treatments are given according to the study protocol. The study lasts about 12 weeks for the main bleeding safety measurements, with some evaluations continuing up to about 25 weeks to monitor adverse events, antibody development, and blood drug concentrations. Throughout the study, participants will have regular assessments to check for bleeding events, strokes, and treatment side effects. Blood tests will measure drug levels and blood clotting times. Researchers will track safety and effectiveness by comparing bleeding incidents and other outcomes between the different treatments. The total participation time covers the treatment period and follow-up visits up to about 25 weeks.
Actively Recruiting
Researchers are evaluating an experimental drug called REGN7508, a monoclonal antibody against Factor XI, compared to apixaban in adults with atrial fibrillation, a condition where the heart beats too fast and irregularly. The study aims to assess the safety and effectiveness of REGN7508 in preventing stroke and systemic embolism. Other aspects include monitoring side effects and whether the body produces antibodies against REGN7508. Participants will be randomly assigned to receive either REGN7508 plus placebo or apixaban plus placebo. Both treatments are given according to the study protocol. This Phase 3, double-blind trial includes two groups running in parallel. The study spans approximately 36 months, during which participants take the assigned treatment and are regularly monitored. During the trial, participants will attend scheduled visits for assessments including monitoring for strokes, systemic embolism, bleeding events, and adverse reactions. Researchers will also check for the presence and levels of anti-drug antibodies against REGN7508. The primary outcomes focus on the time to first stroke or systemic embolism and bleeding events over about three years. Safety and effectiveness will be closely observed throughout the study duration.
1-10 of 15
1